5
Mycobacterium kansasii (Table 2)
➤ In patients with rifampicin-susceptible M. kansasii pulmonary
disease, we suggest a regimen of rifampicin, ethambutol, and either
isoniazid or macrolide (conditional recommendation, very low
certainty in estimates of effect).
➤ We suggest that neither parenteral amikacin nor streptomycin be used
routinely for treating patients with M. kansasii pulmonary disease
(strong recommendation, very low certainty in estimates of effect).
➤ In patients with rifampicin-susceptible M. kansasii pulmonary
disease, we suggest using a regimen of rifampicin, ethambutol, and
either isoniazid or macrolide instead of a fluoroquinolone (conditional
recommendation, very low certainty in estimates of effect).
➤ In patients with rifampicin-resistant M. kansasii or intolerance to
one of the first-line antibiotics we suggest a fluoroquinolone (eg,
moxifloxacin) be used as part of a second-line regimen (conditional
recommendation, very low certainty in estimates of effect).
➤ In patients with noncavitary nodular/bronchiectatic M. kansasii
pulmonary disease treated with a rifampicin, ethambutol, and
macrolide regimen, we suggest either daily or 3 times weekly
treatment (conditional recommendation, very low certainty in
estimates of effect)
➤ In patients with cavitary M. kansasii pulmonary disease treated with
a rifampicin, ethambutol, and macrolide-based regimen, we suggest
daily treatment instead of 3 times weekly treatment (conditional
recommendation, very low certainty in estimates of effect).
➤ In all patients with M. kansasii pulmonary disease treated with
an isoniazid, ethambutol, and rifampicin regimen, we suggest
treatment be given daily instead of 3 times weekly (conditional
recommendation, very low certainty in estimates of effect).
➤ We suggest that patients with rifampin susceptible M. kansasii
pulmonary disease be treated for at least 12 months (conditional
recommendation, very low certainty in estimates of effect).
